Erypeg 75mcg Injection contains Pegylated Recombinant Human Erythropoietin, a long-acting erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and other conditions characterized by insufficient red blood cell production. The pegylation of erythropoietin prolongs its half-life, allowing for less frequent dosing compared to non-pegylated formulations. Erypeg stimulates erythroid progenitor cells in the bone marrow, promoting the synthesis of hemoglobin and increasing red blood cell count, thereby improving oxygen delivery to tissues. This injection is administered subcutaneously or intravenously under medical supervision, with dosage individualized based on patient response and hemoglobin levels. Monitoring of hemoglobin, hematocrit, and iron status is essential during therapy to optimize efficacy and minimize risks such as hypertension, thromboembolic events, and pure red cell aplasia. Erypeg should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. It is contraindicated in patients with hypersensitivity to any component of the formulation. Proper storage and handling are required to maintain product stability. Erypeg 75mcg Injection offers an effective therapeutic option for managing anemia, improving patient quality of life and reducing the need for blood transfusions.